Related Experiment Video

Updated: Feb 26, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.6K

Cabozantinib in the treatment of hepatocellular carcinoma

Mary Linton B Peters1, Rebecca A Miksad1

  • 1Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.

Future Oncology (London, England)
|July 14, 2017
PubMed

Insights

Cabozantinib, a tyrosine kinase inhibitor, shows promise for advanced hepatocellular carcinoma (HCC) patients previously treated with sorafenib. Further Phase III trials are evaluating its efficacy in improving outcomes for this challenging cancer.

Area of Science:

  • Hepatobiliary cancers
  • Medical oncology
  • Drug development

Background:

  • Limited systemic therapy advancements for hepatocellular carcinoma (HCC) between 2007 and 2017.
  • Need for improved treatment options to enhance patient outcomes and quality of life in advanced HCC.

Purpose of the Study:

  • To review the development of cabozantinib for advanced hepatocellular carcinoma (HCC).
  • To summarize the clinical evaluation of cabozantinib in HCC patients.

Main Methods:

  • Cabozantinib is an oral small-molecule tyrosine kinase inhibitor targeting MET, VEGFR2, AXL, and RET.
  • Positive Phase II study results led to a Phase III randomized controlled trial for advanced HCC patients previously treated with sorafenib.
  • Cabozantinib has orphan drug status in the USA for HCC indication.

Main Results:

  • Cabozantinib is approved for metastatic medullary thyroid cancer and previously treated renal cell carcinoma.
  • Ongoing Phase III trial evaluates cabozantinib in advanced HCC patients post-sorafenib therapy.
  • The drug targets key pathways implicated in cancer progression.

Conclusions:

  • Cabozantinib represents a potential new systemic therapy for advanced HCC.
  • Further investigation in Phase III trials is crucial to establish its role in HCC treatment.
  • The development of cabozantinib offers a new avenue for patients with previously treated advanced HCC.
Keywords:
cabozantinibdrug developmenthepatocellular carcinoma

More Related Videos

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.3K
Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

10.8K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
596
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
652